CN111534483B - Application of insulin-like growth factor binding protein 7 activator in chondrogenic differentiation of human umbilical cord mesenchymal stem cells - Google Patents
Application of insulin-like growth factor binding protein 7 activator in chondrogenic differentiation of human umbilical cord mesenchymal stem cells Download PDFInfo
- Publication number
- CN111534483B CN111534483B CN202010444451.XA CN202010444451A CN111534483B CN 111534483 B CN111534483 B CN 111534483B CN 202010444451 A CN202010444451 A CN 202010444451A CN 111534483 B CN111534483 B CN 111534483B
- Authority
- CN
- China
- Prior art keywords
- stem cells
- activator
- mesenchymal stem
- insulin
- umbilical cord
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
- C12N5/0655—Chondrocytes; Cartilage
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/30—Organic components
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
- C12N2506/13—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from connective tissue cells, from mesenchymal cells
- C12N2506/1346—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from connective tissue cells, from mesenchymal cells from mesenchymal stem cells
- C12N2506/1369—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from connective tissue cells, from mesenchymal cells from mesenchymal stem cells from blood-borne mesenchymal stem cells, e.g. MSC from umbilical blood
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Biomedical Technology (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Rheumatology (AREA)
- Chemical & Material Sciences (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Cell Biology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
The invention discloses an application of an insulin-like growth factor binding protein 7 activator in chondrogenic differentiation of human umbilical cord mesenchymal stem cells. The proteoglycan and the type II collagen are cartilage specificity matrix products, the hUC-MSCs in the control induction group have obvious chondrogenic differentiation under the induction of a basic induction culture medium, and the content of the proteoglycan and the type II collagen in the isoalizarin induction group is higher than that in the control induction group, which shows that the isoalizarin in the isoalizarin induction group can further promote the chondrogenic differentiation of the hUC-MSCs and has a dose effect. Isoalizarin may act by activating IGFBP7, a potent IGFBP7 activator. Therefore, the insulin-like growth factor binding protein 7 activator isoalizarin has the function of promoting the chondrogenic differentiation of umbilical cord mesenchymal stem cells in vitro, and can be used for preparing a culture medium for promoting the chondrogenic differentiation of umbilical cord mesenchymal stem cells.
Description
Technical Field
The invention belongs to the field of stem cells, relates to the induced differentiation of umbilical cord mesenchymal stem cells, and particularly relates to an application of an insulin-like growth factor binding protein 7 activator in chondrogenic differentiation of human umbilical cord mesenchymal stem cells.
Background
Cartilage tissue engineering is an important bioengineering approach for treating cartilage damage diseases. In cartilage tissue engineering, the selection of seed cells mainly considers the following points: the cells are easy to obtain and have sufficient sources, and the damage to the material-drawing object is small; lower immune rejection; has induced differentiation potential and strong proliferation and differentiation capacity, etc.; a large number of passage cells can be obtained by in vitro amplification techniques.
Cartilage repair and regeneration have previously focused on chondrocytes, which, despite their ready availability and low immunotype, have acquired a small number of cells and have the disadvantage of dedifferentiation, which limits the development of cartilage repair and regeneration. In the study of inducing chondrogenic differentiation of cells having differentiation potential, cells of various origins have been reported, in which mesenchymal stem cells having an irreplaceable chondrogenic differentiation-inducing ability have been widely noted. Although human mesenchymal stem cells and the like are major targets of cartilage tissue engineering as a stem cell source, an age-limited bone marrow transplantation process is inevitably accompanied by pain and injury, and the utilization rate of bone marrow stromal cells is low, and the proliferation and differentiation ability decreases with age. Compared with other stem cells, the umbilical cord mesenchymal stem cells have low immune prototypes and cartilage forming potential, and can be used as one of cell sources for cartilage tissue engineering.
Human umbilical cord mesenchymal stem cells (hUC-MSCs) are a class of mesenchymal stem cells with multipotential differentiation capacity and self-renewal capacity. The umbilical cord has the advantages of easily-obtained materials, difficulty in pollution, no relation to moral, ethical and legal problems and the like, and is widely used for extracting the hUC-MSCs. Moreover, the in vitro amplification and multidirectional differentiation capacity of the hUC-MSCs is found to be stronger than that of mesenchymal stem cells from other tissues.
The discovery of the von scholar et al shows that the platelet lysate has the function of directionally inducing differentiation of human umbilical cord mesenchymal stem cells into cartilage cells in vitro (the influence of the platelet lysate on in vitro chondrogenic differentiation of human umbilical cord mesenchymal stem cells, journal of Chinese repair and reconstruction surgery, 2011 10).
Luodimei et al found that reduced glutathione has a promoting effect on chondrogenesis induction of human umbilical cord mesenchymal stem cells (influence of reduced glutathione on chondrogenesis induction of human umbilical cord mesenchymal stem cells, journal of bioengineering, China, 2013, 03 phase)
Insulin-like growth factor binding protein 7(IGFBP7) is a secreted glycoprotein, is widely expressed in the body, can be combined with insulin-like growth factors to positively or negatively regulate IGF signal pathway, can also independently play a role, and is involved in regulating important physiological processes of growth differentiation, proliferation, apoptosis, tissue remodeling and the like of cells. The research shows that IGFBP7 has the function of promoting the cartilage differentiation of human umbilical cord mesenchymal stem cells (IGFBP7 promotes the cartilage differentiation of human umbilical cord mesenchymal stem cells, Nature science edition of Nanjing medical university, vol.39, No. 8 of 2019, 8).
Disclosure of Invention
The invention provides an application of an insulin-like growth factor binding protein 7 activator in chondrogenic differentiation of human umbilical cord mesenchymal stem cells in order to overcome the defects in the prior art.
The technical scheme of the invention is as follows:
an application of an insulin-like growth factor binding protein 7 activator in promoting chondrogenic differentiation of umbilical cord mesenchymal stem cells in vitro, wherein the insulin-like growth factor binding protein 7 activator is isoalizarin.
The application of an insulin-like growth factor binding protein 7 activator in preparing a culture medium for promoting chondrogenic differentiation of umbilical cord mesenchymal stem cells, wherein the insulin-like growth factor binding protein 7 activator is isoalizarin.
A culture medium for preparing chondrocytes from umbilical cord mesenchymal stem cells contains an insulin-like growth factor binding protein 7 activator, wherein the insulin-like growth factor binding protein 7 activator is isoalizarin.
The beneficial technical effects are as follows:
the invention discovers that the insulin-like growth factor binding protein 7 activator rubiadin has the function of promoting chondrogenic differentiation of umbilical cord mesenchymal stem cells in vitro and can be used for preparing a culture medium for promoting chondrogenic differentiation of umbilical cord mesenchymal stem cells.
Drawings
FIG. 1 is a diagram of phenotypic flow assays for hUC-MSCs;
FIG. 2 is a comparison of the content of each of the histones;
FIG. 3 is a graph showing the comparison of collagen type II content in each group;
FIG. 4 is a Western blot chart of the expression level of insulin-like growth factor-binding protein 7(IGFBP 7).
Detailed Description
The following examples are intended to illustrate the essence of the present invention, but should not be construed as limiting the scope of the present invention.
First, test materials
DMEM/F12 medium and fetal bovine serum were purchased from Gibco.
Glutamine and diabody were purchased from Nanjing Senega Biotech, Inc.
The PBS buffer solution is prepared according to the formula, stored at 4 ℃ and used up within 24 h.
Collagenase type iv and pancreatin were purchased from shanghai diligent kang biotechnology limited, and used as described herein.
The purity of the isoalizarin is not lower than 98%.
Second, test method
1. Extraction culture and identification of hUC-MSCs
The hUC-MSCs used are the same as those in patents 2020104333269 and 2020104333714, and the preparation and identification methods are as follows:
collecting umbilical cord of newborn produced by normal full-term caesarean section at about 12cm (storing umbilical cord in PBS buffer solution containing 1% double antibody at 4 deg.C, extracting stem cells within 6h, culturing), washing with PBS buffer solution containing 1% double antibody to remove umbilical artery and vein and umbilical cord adventitia, and shearing to about 1mm3Placing the tissue blocks of different sizes in a constant temperature oscillator at 37 deg.C, sequentially adding collagenase IV and pancreasThe cells were extracted by enzyme digestion for 60min and 30min, and then resuspended in DMEM/F12 medium containing 20% FBS, 25mmol/L glutamine and 1% double antibody at 1.0X 106and/mL, inoculating the cells into a cell culture bottle, changing the culture medium after culturing for 4 days, changing the culture medium for 1 time after 2-3 days, and carrying out passage when 80% of the cells are fused. The 5 th generation cells were used for the experiment.
Taking 5 th generation hUC-MSCs, carrying out pancreatin digestion, fully and uniformly blowing to prepare single cell suspension, and adding CD34-PE, CD45-PE, CD73-PE, CD90-PE and CD 105-FITC. Incubating for 30min at room temperature in a dark place, fixing paraformaldehyde, and detecting by a flow cytometer.
2. Induced differentiation of hUC-MSCs into chondrocytes
2.1 grouping
Low concentration of isoalizarin induction group (group a): inducing culture by using a DMEM/F12 culture medium containing 6.25mg/L insulin, 6.25mg/L transferrin, 10 mu g/L transforming growth factor beta 1, 0.1 mu mol/L dexamethasone, 50mg/L vitamin C, 5 mu M isoalizarin (DMSO solubilization), 5% FBS and 1% double antibody;
high concentration of isoalizarin induction group (group B): inducing culture by using a DMEM/F12 culture medium containing 6.25mg/L insulin, 6.25mg/L transferrin, 10 mu g/L transforming growth factor beta 1, 0.1 mu mol/L dexamethasone, 50mg/L vitamin C, 10 mu M isoalizarin (DMSO solubilization), 5% FBS and 1% double antibody;
control induction group (group C): the culture was induced using DMEM/F12 medium (basal induction medium) containing final concentrations of 6.25mg/L insulin, 6.25mg/L transferrin, 10. mu.g/L transforming growth factor beta 1, 0.1. mu. mol/L dexamethasone, 50mg/L vitamin C, 5% FBS and 1% double antibody, to which DMSO vehicle was added in an equal volume to A, B groups.
2.2 Induction culture
Taking 5 th generation well-grown cells hUC-MSCs, digesting with pancreatin, fully and uniformly blowing to prepare single cell suspension, and preparing into 2 × 105And/well inoculating in 6-well plate, and when 85% of cells are fused, replacing culture medium according to the above grouping, inducing and culturing for 18d, and replacing corresponding culture medium every 3 d. Each group is provided with 3 multiple holes.
3. Measurement of proteoglycan content
After 18 days of induction, taking 200 mu L of cell supernatant of each group, adding 40 mu L of papain for digestion for 24 hours; adding 100 mu L of 8mol/L guanidine hydrochloride and 750 mu L of 0.25% alisin blue solution, and reacting for 1h at 4 ℃; centrifuging at 12000r/min for 15min, discarding supernatant, adding 150 μ L isopropanol to dissolve precipitate, and measuring absorbance at 600 nm. And (3) preparing a standard curve by using a series of chondroitin sulfate standard solutions with concentration gradients, and substituting the absorbance value into the standard curve to obtain the proteoglycan content.
4. Determination of type II collagen content
After 18 days of induction, 250 mu L of cell supernatant of each group is taken, 50 mu L of hydroxyproline digestive juice is added, 2mL of hydroxyproline reaction solution is added, water bath at 60 ℃ is carried out for 15min, after cooling, 3500r/min is centrifuged for 10min, 150 mu L of supernatant is taken, and the absorbance value is measured at the wavelength of 560 nm. And (4) preparing a standard curve by using hydroxyproline standard solutions with a series of concentration gradients, and substituting the absorbance value into the standard curve to obtain the type II collagen content.
5. Western blot for measuring expression level of IGFBP7
After 18 days of induction, collecting each group of cells, washing 3 times by PBS to remove the culture medium on the cell surface and the components in the culture medium, cracking the lysate, determining the protein concentration in the lysate by using a BCA kit, performing SDS-PAGE electrophoresis on 50 mu g of protein, transferring the protein onto a PVDF membrane, sealing by 5% skimmed milk powder, adding IGFBP7 and GAPDH (internal reference) for primary incubation at 4 ℃ overnight, washing the membrane by TBS-T (TBS-T) washing liquid on the next day, adding secondary antibody for incubation at room temperature for 1h, performing color development and exposure by an ECL method, photographing by a chemiluminescence imaging system, and analyzing the gray scale by using Image analysis software Image J.
6. Data analysis
In SPSS 17.0, data are presented as mean. + -. SD and tested for t, with P < 0.05 indicating that the difference is statistically significant.
Third, test results
1. Extraction culture and identification results of hUC-MSCs
Phenotypic identification of hUC-MSCs flow results As shown in Table 1 and FIG. 1, CD34-PE and CD45-PE negative expression, CD73-PE, CD90-PE and CD105-FITC positive expression, consistent with the phenotypic characteristics of hUC-MSCs.
TABLE 1 phenotypic identification results of hUC-MSCs
| Expression rate | |
| CD34-PE | 0.35％ |
| CD45-PE | 0.47％ |
| CD73-PE | 95.2％ |
| CD90-PE | 96.8％ |
| CD105-FITC | 98.5％ |
2. Results of proteoglycan content measurement
As shown in table 2 and fig. 2, the content of proteoglycan in the low-concentration rubiadin-induced group (group a) and the content of proteoglycan in the high-concentration rubiadin-induced group (group B) are significantly increased and have a significant dose dependence compared to the control-induced group (group C), and the group B is higher than the group a.
TABLE 2 content of each of the histones
| Group of | Content (μ g/mL) |
| Control Induction group (group C) | 20.9±3.1 |
| Low concentration of rubiadin inducer group (group A) | 35.2±3.4 |
| High concentration of Rubiadin Induction group (group B) | 58.5±3.2 |
3. Determination of type II collagen content
The collagen type ii content in each group is shown in table 3 and fig. 3, and compared with the control induction group (group C), the collagen type ii content in the low-concentration isoalizarin induction group (group a) and the high-concentration isoalizarin induction group (group B) is significantly increased, and there is significant dose dependence, and the group B is higher than the group a.
TABLE 3 collagen content of each group II
| Group of | Content (μ g/mL) |
| Control Induction group (group C) | 197.5±18.2 |
| Low concentration of rubiadin inducer group (group A) | 320.6±21.3 |
| High concentration of Rubiadin Induction group (group B) | 572.8±23.5 |
4. Measurement of expression level of IGFBP7
As shown in fig. 4, compared with the control induction group (group C), the Western blot results show that the content of IGFBP7 protein in the low-concentration isoalizarin induction group (group a) and the high-concentration isoalizarin induction group (group B) is significantly increased, and there is a significant dose dependence, and the group B is higher than the group a.
As known to those skilled in the art, proteoglycan and type II collagen are cartilage specific matrix products, hUC-MSCs in the control induction group have obvious chondrogenic differentiation under the induction of a basic induction culture medium, and the content of proteoglycan and type II collagen in the isoalizarin induction group is higher than that in the control induction group, which indicates that the isoalizarin in the isoalizarin induction group can further promote chondrogenic differentiation of hUC-MSCs and has a dosage effect. Isoalizarin may act by activating IGFBP7, a potent IGFBP7 activator. Therefore, the insulin-like growth factor binding protein 7 activator isoalizarin has the function of promoting the chondrogenic differentiation of the umbilical cord mesenchymal stem cells in vitro, and can be used for preparing a culture medium for promoting the chondrogenic differentiation of the umbilical cord mesenchymal stem cells.
Claims (3)
1. An application of an insulin-like growth factor binding protein 7 activator in promoting chondrogenic differentiation of umbilical cord mesenchymal stem cells in vitro, wherein the insulin-like growth factor binding protein 7 activator is isoalizarin.
2. The application of an insulin-like growth factor binding protein 7 activator in preparing a culture medium for promoting chondrogenic differentiation of umbilical cord mesenchymal stem cells, wherein the insulin-like growth factor binding protein 7 activator is isoalizarin.
3. A culture medium for preparing chondrocytes from umbilical cord mesenchymal stem cells, comprising an insulin-like growth factor binding protein 7 activator, wherein the activator comprises: the insulin-like growth factor binding protein 7 activator is isoalizarin.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010444451.XA CN111534483B (en) | 2020-05-23 | 2020-05-23 | Application of insulin-like growth factor binding protein 7 activator in chondrogenic differentiation of human umbilical cord mesenchymal stem cells |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010444451.XA CN111534483B (en) | 2020-05-23 | 2020-05-23 | Application of insulin-like growth factor binding protein 7 activator in chondrogenic differentiation of human umbilical cord mesenchymal stem cells |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN111534483A CN111534483A (en) | 2020-08-14 |
| CN111534483B true CN111534483B (en) | 2020-12-18 |
Family
ID=71968480
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202010444451.XA Active CN111534483B (en) | 2020-05-23 | 2020-05-23 | Application of insulin-like growth factor binding protein 7 activator in chondrogenic differentiation of human umbilical cord mesenchymal stem cells |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN111534483B (en) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111471648A (en) * | 2020-04-10 | 2020-07-31 | 南京大学 | Preparation method of pretreated and activated mesenchymal stem cells and application of pretreated and activated mesenchymal stem cells in treatment of myeloid leukemia |
| CN112391341B (en) * | 2020-11-30 | 2022-08-19 | 郑州源创吉因实业有限公司 | Application of SDF-1 protein activator in promoting human umbilical cord mesenchymal stem cell proliferation and differentiation in vitro |
| CN113249317A (en) * | 2021-06-17 | 2021-08-13 | 北京国卫生物科技有限公司 | Isolated culture and amplification method and system for human umbilical cord mesenchymal stem cells |
Citations (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1191070A1 (en) * | 2000-09-26 | 2002-03-27 | Coöperatie Rubia | Method for the production of a dye preparation based on madder root |
| CN1644684A (en) * | 2005-01-21 | 2005-07-27 | 周建业 | Method for removing cells for heterogeneous cardiovascular transplant |
| WO2005067489A3 (en) * | 2004-01-05 | 2005-09-29 | Chen Su | Type ii diabetes |
| WO2004091545A3 (en) * | 2003-03-25 | 2006-05-18 | Morinda Inc | Selectively inhibiting estrogen production and providing estrogenic effects in the human body |
| CN101227928A (en) * | 2005-05-27 | 2008-07-23 | 华沙整形外科股份有限公司 | Chondrogenic compositions and methods of use |
| KR20120033699A (en) * | 2010-09-30 | 2012-04-09 | 한국콜마 주식회사 | Cosmetic components comprised of the rubiadin having anti-allergy activity |
| KR20130083784A (en) * | 2012-01-13 | 2013-07-23 | 주식회사 엘지생활건강 | Composition for improving skin wrinkle and enhancing elasticity |
| CN107050005A (en) * | 2017-01-22 | 2017-08-18 | 新乡医学院 | A kind of pharmaceutical composition for treating atherosclerosis and its application |
| CN108531448A (en) * | 2018-03-06 | 2018-09-14 | 安徽瑞杰赛尔生物科技有限公司 | A kind of human mesenchymal stem cell is at chondrocyte induction differential medium and preparation method |
| CN109223739A (en) * | 2018-11-12 | 2019-01-18 | 长春理工大学 | A kind of composition and its preparation method and application |
| EP3572078A1 (en) * | 2018-05-24 | 2019-11-27 | ETH Zurich | Tomm6-interacting extracts and compounds for use in the treatment and prophylaxis of nervous system diseases |
| CN110522808A (en) * | 2018-05-27 | 2019-12-03 | 义乌凌川科技有限公司 | A kind of anti-treating caput femoris necrosis Chinese medicine composition and preparation method thereof |
| CN110755424A (en) * | 2019-11-22 | 2020-02-07 | 南京凡亦达生物科技有限公司 | Pharmaceutical application of elaeagnus pungens A, B used as α -glucosidase inhibitor and further used for preparing hypoglycemic drugs |
| CN111073850A (en) * | 2020-03-24 | 2020-04-28 | 朗姿赛尔生物科技（广州）有限公司 | Culture medium for promoting mesenchymal stem cell differentiation |
| CN111534482A (en) * | 2020-05-23 | 2020-08-14 | 南京凡亦达生物科技有限公司 | Culture medium for chondrogenic differentiation and chondrogenic differentiation of umbilical cord mesenchymal stem cells |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7550014B2 (en) * | 2006-05-01 | 2009-06-23 | Advanced Cosmetic Technologies, Llc | Composition for dyeing keratin fibers and a method of dyeing hair using same |
| US8034126B2 (en) * | 2009-06-15 | 2011-10-11 | Alex Vainshelboim | Henna and vegetable dye based compositions for coloring of human hair |
| US9968645B2 (en) * | 2014-12-31 | 2018-05-15 | Sham Yuen Chan | Method for enhanced production of morinda metabolites |
-
2020
- 2020-05-23 CN CN202010444451.XA patent/CN111534483B/en active Active
Patent Citations (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1191070A1 (en) * | 2000-09-26 | 2002-03-27 | Coöperatie Rubia | Method for the production of a dye preparation based on madder root |
| WO2004091545A3 (en) * | 2003-03-25 | 2006-05-18 | Morinda Inc | Selectively inhibiting estrogen production and providing estrogenic effects in the human body |
| WO2005067489A3 (en) * | 2004-01-05 | 2005-09-29 | Chen Su | Type ii diabetes |
| CN1644684A (en) * | 2005-01-21 | 2005-07-27 | 周建业 | Method for removing cells for heterogeneous cardiovascular transplant |
| CN101227928A (en) * | 2005-05-27 | 2008-07-23 | 华沙整形外科股份有限公司 | Chondrogenic compositions and methods of use |
| KR20120033699A (en) * | 2010-09-30 | 2012-04-09 | 한국콜마 주식회사 | Cosmetic components comprised of the rubiadin having anti-allergy activity |
| KR20130083784A (en) * | 2012-01-13 | 2013-07-23 | 주식회사 엘지생활건강 | Composition for improving skin wrinkle and enhancing elasticity |
| CN107050005A (en) * | 2017-01-22 | 2017-08-18 | 新乡医学院 | A kind of pharmaceutical composition for treating atherosclerosis and its application |
| CN108531448A (en) * | 2018-03-06 | 2018-09-14 | 安徽瑞杰赛尔生物科技有限公司 | A kind of human mesenchymal stem cell is at chondrocyte induction differential medium and preparation method |
| EP3572078A1 (en) * | 2018-05-24 | 2019-11-27 | ETH Zurich | Tomm6-interacting extracts and compounds for use in the treatment and prophylaxis of nervous system diseases |
| CN110522808A (en) * | 2018-05-27 | 2019-12-03 | 义乌凌川科技有限公司 | A kind of anti-treating caput femoris necrosis Chinese medicine composition and preparation method thereof |
| CN109223739A (en) * | 2018-11-12 | 2019-01-18 | 长春理工大学 | A kind of composition and its preparation method and application |
| CN110755424A (en) * | 2019-11-22 | 2020-02-07 | 南京凡亦达生物科技有限公司 | Pharmaceutical application of elaeagnus pungens A, B used as α -glucosidase inhibitor and further used for preparing hypoglycemic drugs |
| CN111073850A (en) * | 2020-03-24 | 2020-04-28 | 朗姿赛尔生物科技（广州）有限公司 | Culture medium for promoting mesenchymal stem cell differentiation |
| CN111534482A (en) * | 2020-05-23 | 2020-08-14 | 南京凡亦达生物科技有限公司 | Culture medium for chondrogenic differentiation and chondrogenic differentiation of umbilical cord mesenchymal stem cells |
Non-Patent Citations (17)
| Title |
|---|
| Alion promotes osteogenesis of bone-marrow-derived mesenchymal stem cells via the ERK1/2-dependent Runx2 signaling pathway;Peng Li等;《J Nat Med》;20180914;第73卷(第1期);第104-113页 * |
| Anthraquinone compounds from Morinda officinalis inhibit osteoclastic bone resorption in vitro;Leilei Bao等;《Chem Biol Ineract》;20111115;第194卷(第2-3期);第97-105页 * |
| Differentially expressed proteins of mesenchymal stem cells derived from human cord blood (hUCB) during osteogenic differentiation;Ji-Soo Kim等;《Biosci Biotechnol Biochem》;20080930;第72卷(第9期);第2309-2317页 * |
| HPLC测定不同产地巴戟天中5种茜草素型蒽醌的含量;史辑等;《中药材》;20150327(第02期);第245-248页 * |
| IGFBP7促进人脐带间充质干细胞的软骨分化;洪芳玲等;《南京医科大学学报(自然科学版)》;20190815(第08期);第1101-1105页 * |
| Morinda citrifolia leaf extract enhances osteogenic differentiation through activation of Wnt/β-catenin signaling;Hanna Gu等;《J Med Food》;20171005;第21卷(第1期);第57-69页 * |
| Synthesis, FT-IR and NMR characterization, antimicrobial activity, cytotoxicity and DNA docking analysis of a new anthraquinone dedrivate compound;Sefa Celik等;《Journal of biomolecular structure and dynamic》;20190402;第38卷(第3期);第756-770页 * |
| Tackling the tumor microenvironment: what challenge does it pose to anticancer therapies?;Fei Chen等;《Protein Cell》;20141130;第5卷(第11期);第816-826页 * |
| The role of small molecules in bone regeneration;Qian-Qian Han等;《Future medicinal chemistry》;20130930;第5卷(第14期);第1671-1684页 * |
| TMARg, a novel anthraquinone isolated from Rubia cordifolia Nakai, increases osteogenesis and mineralization through BMP2 and β-catenin signaling;Kyung-Ran Park等;《International journal of molecular sciences》;20200727;第21卷(第15期);第1-15页 * |
| Umbilical cord blood-mesenchymal stem cells and carvedilol reduce doxorubicin-induced cardiotoxicity: possible role of insulin-like growth factor-1;Hanaa S E Mousa等;《Biomed Pharmacother》;20180930;第105卷;第1192-1204页 * |
| 内皮祖细胞条件培养基对间充质干细胞增殖和成骨分化的影响及其机制;冯文磊等;《吉林大学学报（医学版）》;20150918;第41卷(第2期);第218-224页 * |
| 巴戟天甲基异茜草素对破骨细胞性骨吸收的影响;鲍蕾蕾等;《解放军药学学报》;20100406;第25卷(第6期);第505-509页 * |
| 淫羊藿素通过Wnt/β-catenin信号通路促进BMSCs成软骨分化;汪建样等;《中国中药杂志》;20160215;第41卷(第4期);第694-699页 * |
| 茜草水溶性提取物减少高脂饮食诱导的肥胖大鼠内脏脂肪;严克敏等;《基础医药与临床》;20170927;第37卷(第9期);第1231-1236页 * |
| 茜草素在体外抗菌活性的研究;宋文刚等;《中国地方病防治杂志》;20070416;第22卷(第1期);第69-70页 * |
| 蒽醌类化合物抗菌活性及其机制研究进展;邓丽红等;《中国新药杂志》;20161115(第21期);第2450-2455页 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN111534483A (en) | 2020-08-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN111534483B (en) | Application of insulin-like growth factor binding protein 7 activator in chondrogenic differentiation of human umbilical cord mesenchymal stem cells | |
| US10465167B2 (en) | Adjuvant for rapid proliferation of human mesenchymal stem cells in vitro, method for rapid proliferation of human mesenchymal stem cells in vitro, method for growth factor harvested from rapid proliferation of human mesenchymal stem cells in vitro and use thereof | |
| CN110974944B (en) | Mesenchymal stem cell composite active factor freeze-dried powder and preparation method and application thereof | |
| CN112553147B (en) | Growth factor composition for promoting proliferation of muscle stem cells and application thereof | |
| Patil et al. | Silk fibroin-alginate based beads for human mesenchymal stem cell differentiation in 3D | |
| CN109706115B (en) | Construction method of mouse bone marrow mesenchymal stem cell line | |
| Nejaddehbashi et al. | Isolating human dermal fibroblasts using serial explant culture | |
| He et al. | Phenotypic redifferentiation of dedifferentiated microtia chondrocytes through a three-dimensional chondrogenic culture system | |
| CN114891734A (en) | Immortalized yak rumen fibroblast line and construction and application thereof | |
| CN111534482B (en) | Culture medium for chondrogenic differentiation and chondrogenic differentiation of umbilical cord mesenchymal stem cells | |
| CN110747162B (en) | Application of small molecular compound 4-aminobiphenyl in promoting stem cell proliferation and chondrogenic differentiation | |
| CN111534486A (en) | Application of active ingredient to inducing chondrogenic differentiation of mesenchymal stem cells and chondrogenic differentiation induction culture medium | |
| CN107164325B (en) | The preparation method and kit of the oligodendroglia in the source MSCs | |
| CN108048390B (en) | Method for preparing vascular endothelial cells and special kit thereof | |
| RU2576842C2 (en) | Method of producing myoblasts, use of gingival biopsy material, myoblasts preparation for treating pathologies of muscular tissue and method for production thereof | |
| CN114703132A (en) | Application of extracellular vesicles in preparation of culture medium for relieving iPSC-MSCs (induced pluripotent stem cells-mesenchymal stem cells) aging | |
| CN111518760A (en) | Culture medium for promoting in-vitro proliferation and differentiation of umbilical cord mesenchymal stem cells | |
| CN111961643A (en) | Induction method for differentiation of stem cells into chondrocytes | |
| CN104450608B (en) | Promote the adjuvant of Human Meta's stem cell proliferation, expand Human Meta's stem cell methods, medical composition, growth factor and application thereof | |
| TWI486447B (en) | Adjuvant for rapid proliferation of human mesenchymal stem cells in vitro, method for rapid proliferation of human mesenchymal stem cells in vitro, method for growth factor harvested from rapid proliferation of human mesenchymal stem cells in vitro and u | |
| TWI555847B (en) | Culture and production of adipose - derived stem cells and their stem cell secretions | |
| CN111388503A (en) | Human umbilical cord mesenchymal stem cell-derived exosome and application thereof in resisting skin aging and improving skin elasticity of human | |
| CN111450118A (en) | Human umbilical cord mesenchymal stem cell-derived exosome and application thereof in resisting skin aging and improving skin elasticity of human | |
| CN113717933B (en) | Application of FGF7 in preparation of stem cell expansion and phenotype maintaining reagent | |
| CN118240762B (en) | Culture method for simulating microgravity-induced reprogramming of primary cancer cells and application of culture method |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| TA01 | Transfer of patent application right |
Effective date of registration: 20201130 Address after: Room 301, 3 / F, building 3, self made, No. 6, Nanjiang 2nd Road, Zhujiang street, Nansha District, Guangzhou City, Guangdong Province Applicant after: Guangdong Yijia Regenerative Medicine Research Institute Co.,Ltd. Address before: No. 268, Lidao Road, Baguazhou street, Qixia District, Nanjing City, Jiangsu Province Applicant before: Nanjing fanyida Biotechnology Co.,Ltd. |
|
| TA01 | Transfer of patent application right | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |